Comparative Pharmacology
Head-to-head clinical analysis: CALAN SR versus CARDENE IN 5 0 DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALAN SR versus CARDENE IN 5 0 DEXTROSE IN PLASTIC CONTAINER.
CALAN SR vs CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It causes vasodilation and decreases systemic vascular resistance.
Oral: 180–240 mg once daily; maximum 480 mg/day.
Intravenous infusion: initial dose 5 mg/hour, titrate by 2.5-5 mg/hour every 15-30 minutes as needed; maximum 15 mg/hour. Oral: 20 mg three times daily initially, then 30-40 mg three times daily.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours (average ~8 hours) after single oral dose; may increase to 12-16 hours with chronic dosing due to saturable hepatic metabolism; clinical context: requires dosing adjustments in hepatic impairment.
2 to 4 hours in healthy subjects; increased in hepatic impairment (up to 7 hours) and in elderly. No significant change in renal impairment.
Approximately 70% of the dose is excreted as metabolites in the urine; 3-4% as unchanged drug; 25% eliminated in feces via biliary excretion.
Primarily hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for approximately 60-70% of total elimination, with renal excretion of metabolites approximately 30-40%.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker